Campos Highlights Biggest Advancement in Ovarian Cancer This Year

Susana M. Campos, MD, discusses her thoughts on the biggest advancements in ovarian cancer in 2018. PARP inhibitors are great at putting these patients in remission; however, the challenge with this lies in keeping them in remission.

Susana M. Campos, MD, gynecologic oncologist at Dana-Farber Cancer Institute and assistant professor of medicine at Harvard Medical School, discusses her thoughts on the biggest advancements in ovarian cancer in 2018. PARP inhibitors are great at putting these patients in remission; however, the challenge with this lies in keeping them in remission.

According to Campos, most patients that receive PARP inhibitors will relapse. Nevertheless, PARP inhibitors such as olaparib (Lynparza), niraparib (Zejula), and rucaparib (Rubraca) have dramatically improved progression-free survival and have made an amazing contribution to the field, Campos says.